Review article: nucleos(t)ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease (Q38168296)

30 August 2017

Review article: nucleos(t)ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease (English)

1 reference

30 August 2017

1 reference

1 reference

1 reference

George Papatheodoridis

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24299322%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

author name string

C Pipili

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24299322%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

E Cholongitas

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24299322%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

language of work or name

English

0 references

publication date

29 October 2013

1 reference

Alimentary Pharmacology & Therapeutics

30 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24299322%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

volume

39

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24299322%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24299322%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

page(s)

35-46

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24299322%20AND%20SRC:MED&resulttype=core&format=json

Chronic hepatitis B: update 2009

10 June 2020

cites work

1 reference

Why do I treat HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues?

21 January 2018

1 reference

EASL clinical practice guidelines: Management of chronic hepatitis B virus infection

21 January 2018

1 reference

Therapeutic strategies in the management of patients with chronic hepatitis B virus infection.

21 January 2018

1 reference

Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance

21 January 2018

1 reference

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

Telbivudine versus lamivudine in patients with chronic hepatitis B

21 January 2018

1 reference

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group

21 January 2018

1 reference

Long-term safety of lamivudine treatment in patients with chronic hepatitis B.

21 January 2018

1 reference

Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease

21 January 2018

1 reference

Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

21 January 2018

1 reference

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.

21 January 2018

1 reference

Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.

21 January 2018

1 reference

Review article: current management of chronic hepatitis B.

21 January 2018

1 reference

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years

21 January 2018

1 reference

2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B.

21 January 2018

1 reference

Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B.

21 January 2018

1 reference

Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.

21 January 2018

1 reference

Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy

21 January 2018

1 reference

Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.

21 January 2018

1 reference

Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues

21 January 2018

1 reference

21 January 2018

1 reference

Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B.

21 January 2018

1 reference

Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naïve patients with HBV-related decompensated cirrhosis.

21 January 2018

1 reference

52-week efficacy and safety of telbivudine with conditional tenofovir intensification at week 24 in HBeAg-positive chronic hepatitis B

21 January 2018

1 reference

Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs

21 January 2018

1 reference

Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection

21 January 2018

1 reference

Drug-induced renal failure: update on new medications and unique mechanisms of nephrotoxicity

21 January 2018

1 reference

Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil

21 January 2018

1 reference

Adefovir treatment for chronic hepatitis B in heart transplant recipients

21 January 2018

1 reference

Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B

21 January 2018

1 reference

Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence

21 January 2018

1 reference

Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions

21 January 2018

1 reference

Hypophosphataemic osteomalacia in patients on adefovir dipivoxil.

21 January 2018

1 reference

Long-term adefovir plus lamivudine therapy does not decrease creatinine clearance in HBeAg-negative chronic hepatitis B patients

21 January 2018

1 reference

Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study

21 January 2018

1 reference

Association between tenofovir exposure and reduced kidney function in a cohort of HIV-positive patients: results from 10 years of follow-up

21 January 2018

1 reference

Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients

21 January 2018

1 reference

Hepatitis B virus-associated nephropathy.

21 January 2018

1 reference

Role of hepatitis B virus infection in pathogenesis of IgA nephropathy

21 January 2018

1 reference

Complete remission of nephrotic syndrome of hepatitis B virus-associated membranous glomerulopathy after lamivudine monotherapy

21 January 2018

1 reference

Lamivudine for the treatment of membranous glomerulopathy secondary to chronic Hepatitis B infection

21 January 2018

1 reference

Experience of anti-viral therapy in hepatitis B-associated membranous nephropathy, including Lamivudine-resistant strains

21 January 2018

1 reference

Lamivudine in hepatitis B-associated membranous nephropathy

21 January 2018

1 reference

Hepatitis B virus-related membranous nephropathy treated with entecavir

21 January 2018

1 reference

Focal segmental glomerulosclerosis as a complication of hepatitis B virus infection

21 January 2018

1 reference

Complete remission of hepatitis B virus-related membranous nephropathy after entecavir monotherapy

21 January 2018

1 reference

Meta-analysis of combined therapy for adult hepatitis B virus-associated glomerulonephritis

21 January 2018

1 reference

Hepatitis B virus infection and the dialysis patient

21 January 2018

1 reference

Randomised placebo-controlled trial of hepatitis B surface antigen vaccine in french haemodialysis units: II, Haemodialysis patients

21 January 2018

1 reference

Navigating the maze of hepatitis B treatments

21 January 2018

1 reference

Prophylaxis and treatment of hepatitis B in immunocompromised patients

21 January 2018

1 reference

Transjugular liver biopsy in patients with end-stage renal disease.

21 January 2018

1 reference

Single dose pharmacokinetics of lamivudine in subjects with impaired renal function and the effect of haemodialysis

21 January 2018

1 reference

Pharmacokinetics and dosing recommendations of tenofovir disoproxil fumarate in hepatic or renal impairment

21 January 2018

1 reference

Efficacy and pharmacokinetics of adefovir dipivoxil liquid suspension in patients with chronic hepatitis B and renal impairment

21 January 2018

1 reference

An open-label study of lamivudine for chronic hepatitis B in six patients with chronic renal failure before and after kidney transplantation

21 January 2018

1 reference

Lamivudine in renal transplant candidates with chronic hepatitis B infection

21 January 2018

1 reference

Efficiency and safety of lamivudine therapy in patients with chronic HBV infection, dialysis or after kidney transplantation.

21 January 2018

1 reference

Excellent outcome of Lamivudine treatment in patients with chronic renal failure and hepatitis B virus infection

21 January 2018

1 reference

Efficacy and safety of adefovir dipivoxil in kidney recipients, hemodialysis patients, and patients with renal insufficiency

21 January 2018

1 reference

Clinical and virological effects during two years of ongoing adefovir dipivoxil in the treatment of lamivudine-resistant chronic hepatitis B infection

21 January 2018

1 reference

Successful treatment of fibrosing cholestatic hepatitis using adefovir dipivoxil in a patient with cirrhosis and renal insufficiency

21 January 2018

1 reference

Pharmacokinetics of tenofovir in haemodialysis

21 January 2018

1 reference

HBsAg seropositive status and survival after renal transplantation: meta-analysis of observational studies

21 January 2018

1 reference

The long-term virologic and pathologic impact of renal transplantation on chronic hepatitis B virus infection

21 January 2018

1 reference

Impact of hepatitis B and C virus infections on kidney transplantation: a single center experience

21 January 2018

1 reference

Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients

21 January 2018

1 reference

Evaluation of adult kidney transplant candidates

21 January 2018

1 reference

Acute humoral rejection in hepatitis C-infected renal transplant recipients receiving antiviral therapy.

21 January 2018

1 reference

Membranous nephropathy in an HIV-positive patient complicated with hepatitis B virus infection

21 January 2018

1 reference

Hepatitis B treatment: Lessons for the nephrologist.

21 January 2018

1 reference

Lamivudine for the treatment of hepatitis B virus-related liver disease after renal transplantation: meta-analysis of clinical trials

21 January 2018

1 reference

Treatment with adefovir dipivoxil in a renal transplant patient with renal insufficiency and lamivudine-resistant hepatitis B infection

21 January 2018

1 reference

Response to adefovir or entecavir in renal allograft recipients with hepatitic flare due to lamivudine-resistant hepatitis B.

21 January 2018

1 reference

Entecavir therapy for adefovir-resistant hepatitis B virus infection in kidney and liver allograft recipients

21 January 2018

1 reference

Long-term outcome of renal transplant recipients with chronic hepatitis B infection-impact of antiviral treatments.

21 January 2018

1 reference

Tenofovir therapy in hepatitis B virus-positive solid-organ transplant recipients

21 January 2018

1 reference

Safety of using hepatitis B virus core antibody or surface antigen-positive donors in kidney or pancreas transplantation

21 January 2018

1 reference

Kidney transplantation from hepatitis B surface antigen positive donors into hepatitis B surface antibody positive recipients: a prospective nonrandomized controlled study from a single center.

21 January 2018

1 reference